Abstract: A lower vehicle-body structure of a vehicle may include: a floor panel; a side sill; and a frame member that extends in the front-rear direction on the vehicle-width-direction inner side of the side sill and includes a front-rear extended portion that is in abutment against the side sill on the vehicle-width-direction inner side and extends in the vehicle front-rear direction along the side sill. The front-rear extended portion may include: a bottom face portion; an inner wall portion; and an inner-side flange that extends to the vehicle-width-direction inner side from a distal end portion of the inner wall portion and is joined to the floor panel. Deformation facilitating facilitators that facilitate deformation of the bottom face portion in the vehicle width direction when a collision load in the vehicle width direction is input may be formed in the bottom face portion.

Abstract: To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.

Abstract: To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.

Abstract: A transglutaminase activator containing at least one kind selected from the group consisting of an extract from Justicia procumbens, an extract from Peristrophe japonica, and a compound represented by Formula (1), as an active ingredient: wherein R1 and R2 represent a hydrogen atom, a hydroxyl group, or an alkoxy group having 1 to 4 carbon atoms; R3 represents a hydrogen atom, or a group for forming a methylenedioxy group by bonding with R2; R4 and R5 represent a hydrogen atom, or a group for forming a methylenedioxy group by bonding with each other; R6 represents a hydrogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms, an acyloxy group having 1 to 4 carbon atoms, or a specific sugar residue.

Abstract: The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a very safe skin whitening agent, melanin production inhibitor, and dopa oxidase activity inhibitor. Use of kitsunenomago or an organic solvent extract thereof to inhibit the dopa oxidase activity.

Abstract: Provided is an anesthetic solution-filled cartridge-type electric dental syringe, wherein the plunger has been shortened but the plunger can nevertheless be extended to the distance necessary to evacuate the anesthetic solution from the cartridge. The syringe comprises: an extension tube into which a plunger is movably inserted, the extension tube being movably disposed in the through hole of a support block and having racks formed in the side surface thereof that are coordinated with the racks of the plunger; and a means for the plunger to draw the extension tube to engage the racks of the extension tube with a pinion when the plunger reaches the middle of the distance corresponding to the anesthetic solution accommodation length of the cartridge. By the engagement of the racks of the extension tube with the pinion, the plunger moves together with the extension tube for the remainder of the distance corresponding to the anesthetic solution accommodation length of the cartridge.

Abstract: The invention provides a method for inhibiting dopa oxidase activity, for inhibiting melanin production, or for whitening skin using haguro-so or an organic solvent extract thereof, or a compound of formula (I):

Abstract: A transglutaminase activator containing at least one kind selected from the group consisting of an extract from Justicia procumbens, an extract from Peristrophe japonica, and a compound represented by Formula (1), as an active ingredient: wherein R1 and R2 represent a hydrogen atom, a hydroxyl group, or an alkoxy group having 1 to 4 carbon atoms; R3 represents a hydrogen atom, or a group for forming a methylenedioxy group by bonding with R2; R4 and R5 represent a hydrogen atom, or a group for forming a methylenedioxy group by bonding with each other; R6 represents a hydrogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms, an acyloxy group having 1 to 4 carbon atoms, or a specific sugar residue.

Abstract: The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Abstract: A motorized syringe for use with two types of dental anesthetic solution-filled cartridges, having a plunger plug in the 1.8 ml cartridge pushed by a push rod by a length required to push a plunger plug in the 1.0 ml cartridge. The syringe includes a cartridge holder for use with 1.0 ml and 1.8 ml cartridges, the push rod having a 1.0 ml position and a 1.8 ml position drawn back from the 1.0 ml position so that push rod movement can end at a common terminal position for both, a sleeve adapted to receive the push rod rear end when pushed back from the common terminal position, and to be not interfered with by the push rod's rear end when it is in the 1.0 ml position, the sleeve being pushed rearward with the push rod's rear end when pushed back to the 1.8 ml position.

Abstract: Provided are a very safe skin whitening agent, melanin production inhibitor, and dopa oxidase activity inhibitor. Use of kitsunenomago or an organic solvent extract thereof to inhibit the dopa oxidase activity.

Abstract: Provided is an anesthetic solution-filled cartridge-type electric dental syringe, wherein the plunger has been shortened but the plunger can nevertheless be extended to the distance necessary to evacuate the anesthetic solution from the cartridge. The syringe comprises: an extension tube (11) into which a plunger (5) is movably inserted, the extension tube being movably disposed in the through hole (14) of a support block (13) and having racks (15, 15) formed in the side surface thereof that are coordinated with the racks (9) of the plunger; and a means for the plunger to draw the extension tube to engage the racks (15, 15) of the extension tube with a pinion (21) when the plunger reaches the middle of the distance corresponding to the anesthetic solution accommodation length of the cartridge.

Abstract: Use of haguro-so or an organic solvent extract thereof, or a compound represented by the following formula (I) or a salt thereof, for inhibiting a dopa oxidase activity, for inhibiting melanin production, or for whitening the skin; in the formula (I), R1 and R2, being the same or different, each represent a hydroxyl group, or a C1-4 linear or branched alkoxy group, or R1 and R2 together form a methylenedioxy group; R3 and R4, being the same or different, each represent a hydroxyl group, or a C1-4 linear or branched alkoxy group, or R3 and R4 together form a methylenedioxy group; R5 represents a hydrogen atom, a hydroxyl group, a C1-5 linear or branched alkoxy group, a C1-4 acyl group, or a sugar residue selected from the group consisting of (D-apio-?-D-furanosyl)oxy, (?-D-glucopyranosyl)oxy, (3-O,4-O-dimethyl-D-xylopyranosyl)oxy, (2-O,3-O,4-O-trimethyl-?-D-xylopyranosyl)oxy, and (3-O-methyl-?-D-glucopyranosyl)oxy; R6 and R7 are each a hydrogen atom and R8 and R9 together represent an oxygen atom, or R8 and R9

Abstract: The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: A dopa oxidase inhibitor, a skin-lightening agent and an external preparation for skin; comprising an extract of at least one plant selected from the group consisting of Melia toosendan Sieb. et Zucc., Amomum tsao-ka Crevost et Lemaire. Senecio gracilis and Veratrum nigrum L., or a compound represented by the following Formula (1), as an active ingredient: wherein R represents an acyl group having 1 to 5 carbon atom(s).

Abstract: The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.